U.S. Markets close in 4 hrs 18 mins

Momenta Rockets After Analysts Get Bullish on Biopharma's Newest Treatment

In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Momenta's proposed inflammatory blood disease therapy, M254, could provide an alternative to the current, IV-based treatment, with a potential market of $6 billion, according to a JPMorgan analyst.